Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:07 am
Author: Getaka|Social: XLinkedIn

Ind-Swift Laboratories Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹5.59Overvalued by 95.95%vs CMP ₹138.00

P/E (23.8) × ROE (0.2%) × BV (₹160.00) × DY (2.00%)

₹228.16Undervalued by 65.33%vs CMP ₹138.00
MoS: +39.5% (Strong)Confidence: 48/100 (Moderate)Models: 5 Under, 4 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹11.7924%Over (-91.5%)
Graham NumberEarnings₹380.7514%Under (+175.9%)
Earnings PowerEarnings₹266.9712%Under (+93.5%)
DCFCash Flow₹744.6912%Under (+439.6%)
Net Asset ValueAssets₹160.028%Under (+16%)
EV/EBITDAEnterprise₹2.2010%Over (-98.4%)
Earnings YieldEarnings₹402.708%Under (+191.8%)
ROCE CapitalReturns₹106.588%Over (-22.8%)
Revenue MultipleRevenue₹34.386%Over (-75.1%)
Consensus (9 models)₹228.16100%Undervalued
Key Drivers: EPS CAGR 110.8% lifts DCF — verify sustainability. | ROE 0.2% is below cost of equity.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 110.8%

*Investments are subject to market risks

Investment Snapshot

38
Ind-Swift Laboratories Ltd scores 38/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health38/100 · Weak
ROCE 0.8% WeakROE 0.2% WeakD/E 2.56 High debtInterest Coverage 0.0x RiskyProfitable 3/5 years Mixed
Smart Money70/100 · Strong
FII holding up 9.53% (6mo) AccumulatingDII holding down 0.75% MF sellingPromoter increased by 3.56% Positive
Earnings Quality30/100 · Weak
OPM contracting (19% → 8%) DecliningWorking capital: 141 days Capital intensive
Quarterly Momentum35/100 · Weak
Revenue (4Q): -15% YoY DecliningProfit (4Q): -49% YoY DecliningOPM: 2.8% (up 7.9% YoY) Margin expansion
Industry Rank35/100 · Weak
P/E 23.8 vs industry 53.8 Cheaper than peersROCE 0.8% vs industry 16.4% Below peersROE 0.2% vs industry 15.2% Below peers3Y sales CAGR: -19% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:07 am

Market Cap 1,128 Cr.
Current Price 138
Intrinsic Value₹228.16
High / Low 152/67.2
Stock P/E23.8
Book Value 160
Dividend Yield0.00 %
ROCE0.78 %
ROE0.18 %
Face Value 10.0
PEG Ratio0.21

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Ind-Swift Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Ind-Swift Laboratories Ltd 1,128 Cr. 138 152/67.223.8 1600.00 %0.78 %0.18 % 10.0
TTK Healthcare Ltd 1,107 Cr. 784 1,402/73515.9 7681.28 %9.26 %6.89 % 10.0
Venus Remedies Ltd 1,151 Cr. 861 950/28615.1 4450.00 %11.1 %7.16 % 10.0
Hester Biosciences Ltd 1,162 Cr. 1,366 2,350/1,23928.4 3970.51 %9.71 %9.18 % 10.0
Lincoln Pharmaceuticals Ltd 1,191 Cr. 595 679/44013.6 3570.30 %17.3 %12.8 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Ind-Swift Laboratories Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 312.69304.25310.34289.71287.51528.5733.1711.96128.80138.24152.73152.64150.85
Expenses 258.93240.58250.05224.02235.82437.3642.9123.76135.45147.44149.13151.17146.68
Operating Profit 53.7663.6760.2965.6951.6991.21-9.74-11.80-6.65-9.203.601.474.17
OPM % 17.19%20.93%19.43%22.67%17.98%17.26%-29.36%-98.66%-5.16%-6.66%2.36%0.96%2.76%
Other Income 8.36-16.445.617.407.11458.2311.1413.0115.91220.3414.5817.8621.73
Interest 22.3821.8220.3821.1421.052.960.170.4110.03-26.761.152.010.67
Depreciation 15.399.2913.8913.1913.5619.550.250.225.817.446.686.988.84
Profit before tax 24.3516.1231.6338.7624.19526.930.980.58-6.58230.4610.3510.3416.39
Tax % -13.43%255.40%45.02%17.88%19.31%6.29%-3.06%31.03%-16.41%3.55%16.52%22.24%41.92%
Net Profit 27.50-25.1217.2431.6619.42493.680.940.41-5.49222.278.777.999.54
EPS in Rs 4.65-4.252.925.363.2983.550.160.07-0.9336.671.450.981.17

Last Updated: February 5, 2026, 1:08 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 1:16 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 9656606537167657577808911,0391,2071,709562594
Expenses 9065715466106316306357098379781,403581594
Operating Profit 5989107106134126144183202229306-190
OPM % 6%13%16%15%18%17%19%21%19%19%18%-3%0%
Other Income -19-31115161203323377476305275
Interest 11711710688289210710096921043-23
Depreciation 6684858887104908713157802430
Profit before tax -142-143-83-553650-20181387598258268
Tax % -14%-17%-29%-29%39%42%7%117%117%45%10%3%
Net Profit -122-119-59-392229-21-3-248539250249
EPS in Rs -29.79-29.14-14.33-8.754.856.09-3.59-0.53-0.368.0691.1841.3240.27
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)2.46%50.42%33.90%156.41%31.82%-172.41%85.71%33.33%2500.00%1022.92%-53.62%
Change in YoY Net Profit Growth (%)0.00%47.96%-16.52%122.51%-124.59%-204.23%258.13%-52.38%2466.67%-1477.08%-1076.53%

Ind-Swift Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-2%
5 Years:-6%
3 Years:-19%
TTM:-62%
Compounded Profit Growth
10 Years:10%
5 Years:30%
3 Years:205%
TTM:-88%
Stock Price CAGR
10 Years:14%
5 Years:24%
3 Years:20%
1 Year:-32%
Return on Equity
10 Years:2%
5 Years:6%
3 Years:10%
Last Year:4%

Last Updated: September 5, 2025, 7:30 am

Balance Sheet

Last Updated: December 10, 2025, 2:51 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 41424245464860606060676982
Reserves 6845534764865075405815445416227451,1041,226
Borrowings 1,3551,4131,4571,2421,0831,1481,0311,0059538622174122
Other Liabilities 258236240364387188198210247280432224215
Total Liabilities 2,3392,2442,2152,1382,0231,9241,8701,8181,8011,8241,4601,4381,544
Fixed Assets 1,1741,1171,0991,042934914843753630587192273285
CWIP 781137870692011191085100
Investments 17181818181917362930112213312
Other Assets 1,0709971,0201,0071,0029729981,0111,1311,1991,106952947
Total Assets 2,3392,2442,2152,1382,0231,9241,8701,8181,8011,8241,4601,4381,544

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 098799673-64125135150195-187-25
Cash from Investing Activity + 0-35-29-31-17-12-9-105-13-28-110
Cash from Financing Activity + 0-64-48-69-62100-133-124-141-18665769
Net Cash Flow 0-13-4-623-17114-4443-66
Free Cash Flow 059496352-79114131137182-250-51
CFO/OP 0%111%74%90%54%-51%87%74%74%85%-61%131%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow58.0088.00106.00105.00133.00125.00143.00182.00-751.00-633.0089.00-60.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 16821520818219416918617716015348107
Inventory Days 1823123683052912843153012882426145
Days Payable 1031201379111811412411111811352140
Cash Conversion Cycle 2474074393963673393773673302822112
Working Capital Days 129141-26-97-492172482532532342141
ROCE %0%1%2%2%4%4%5%7%7%13%20%3%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Feb 2026
Promoters 42.01%42.01%42.01%42.01%42.01%42.01%42.01%40.94%40.94%39.49%39.49%43.05%
FIIs 0.08%0.17%0.31%0.26%1.27%0.65%0.46%3.07%4.27%14.80%14.33%13.80%
DIIs 19.49%19.49%18.73%8.03%0.94%0.94%0.94%0.91%0.91%0.68%0.68%0.16%
Public 38.44%38.34%38.96%49.72%55.81%56.41%56.61%55.08%53.88%45.02%45.50%42.99%
No. of Shareholders 22,96225,40524,63322,43925,46128,88328,75228,11728,70943,78042,12140,404

Shareholding Pattern Chart

No. of Shareholders

Ind-Swift Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 37.2571.248.10-0.36-0.53
Diluted EPS (Rs.) 35.2171.248.10-0.36-0.53
Cash EPS (Rs.) 40.0080.3517.5921.5514.07
Book Value[Excl.RevalReserv]/Share (Rs.) 170.88157.6483.3667.6165.66
Book Value[Incl.RevalReserv]/Share (Rs.) 170.88157.64114.02100.47100.90
Revenue From Operations / Share (Rs.) 81.71216.78201.87173.68149.04
PBDIT / Share (Rs.) 9.0250.7043.9239.9834.36
PBIT / Share (Rs.) 5.4641.6834.3318.0719.77
PBT / Share (Rs.) 37.5098.4614.472.103.01
Net Profit / Share (Rs.) 36.4471.338.00-0.35-0.52
NP After MI And SOA / Share (Rs.) 36.4471.247.96-0.35-0.52
PBDIT Margin (%) 11.0323.3821.7523.0123.05
PBIT Margin (%) 6.6719.2217.0010.4013.26
PBT Margin (%) 45.8945.417.161.202.02
Net Profit Margin (%) 44.6032.903.96-0.20-0.35
NP After MI And SOA Margin (%) 44.5932.863.94-0.20-0.35
Return on Networth / Equity (%) 21.3245.199.54-0.53-0.80
Return on Capital Employeed (%) 3.0826.0914.137.367.86
Return On Assets (%) 17.4136.132.60-0.11-0.17
Long Term Debt / Equity (X) 0.010.011.512.102.25
Total Debt / Equity (X) 0.020.011.732.352.56
Asset Turnover Ratio (%) 0.430.850.660.540.46
Current Ratio (X) 3.922.993.143.223.00
Quick Ratio (X) 3.412.941.961.941.81
Inventory Turnover Ratio (X) 9.015.701.521.331.23
Interest Coverage Ratio (X) 21.245.862.852.502.05
Interest Coverage Ratio (Post Tax) (X) 10.361.681.810.970.96
Enterprise Value (Cr.) 189.85165.501173.711328.011424.06
EV / Net Operating Revenue (X) 0.330.120.971.281.60
EV / EBITDA (X) 3.060.554.475.556.93
MarketCap / Net Operating Revenue (X) 1.030.450.270.380.48
Price / BV (X) 0.490.620.660.981.10
Price / Net Operating Revenue (X) 1.030.450.270.380.48
EarningsYield 0.430.720.14-0.01-0.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Ind-Swift Laboratories Ltd. is a Public Limited Listed company incorporated on 04/01/1995 and has its registered office in the State of Chandigarh, India. Company's Corporate Identification Number(CIN) is L24232CH1995PLC015553 and registration number is 015553. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 549.65 Cr. and Equity Capital is Rs. 68.74 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSCO 850, Shivalik Enclave, Chandigarh Chandigarh 160101Contact not found
Management
NamePosition Held
Mr. Navrattan MunjalChairman & Managing Director
Mr. Himanshu JainJoint Managing Director
Mr. Rishav MehtaExecutive Director
Mr. Sahil MunjalExecutive Director
Mr. Rajinder Kumar GuptaIndependent Director
Mr. Prabhat KhuranaIndependent Director
Mr. Subodh GuptaIndependent Director
Ms. Neerja ChathleyIndependent Woman Director

FAQ

What is the intrinsic value of Ind-Swift Laboratories Ltd and is it undervalued?

As of 14 April 2026, Ind-Swift Laboratories Ltd's intrinsic value is ₹228.16, which is 65.33% higher than the current market price of ₹138.00, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (0.18 %), book value (₹160), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Ind-Swift Laboratories Ltd?

Ind-Swift Laboratories Ltd is trading at ₹138.00 as of 14 April 2026, with a FY2026-2027 high of ₹152 and low of ₹67.2. The stock is currently near its 52-week high. Market cap stands at ₹1,128 Cr..

How does Ind-Swift Laboratories Ltd's P/E ratio compare to its industry?

Ind-Swift Laboratories Ltd has a P/E ratio of 23.8, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Ind-Swift Laboratories Ltd financially healthy?

Key indicators for Ind-Swift Laboratories Ltd: ROCE of 0.78 % is on the lower side compared to the industry average of 16.35%; ROE of 0.18 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Ind-Swift Laboratories Ltd profitable and how is the profit trend?

Ind-Swift Laboratories Ltd reported a net profit of ₹250 Cr in Mar 2025 on revenue of ₹562 Cr. Compared to ₹-2 Cr in Mar 2022, the net profit shows an improving trend.

Does Ind-Swift Laboratories Ltd pay dividends?

Ind-Swift Laboratories Ltd has a dividend yield of 0.00 % at the current price of ₹138.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Ind-Swift Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports